Merck explores external innovation and partnership opportunity in Korea at KPAC 2017 and Bio Korea 2017

Printer-friendly versionPrinter-friendly versionSend by emailSend by email
Tuesday, April 11th, 2017
merck

(Second from left) Michael Chen, Head of External Innovation based in Beijing R&D Hub of Merck Global R&D

Seoul, Korea, April 11, 2017/Korea IT Times - Merck Korea (Managing Director: Michael Grund), the Korean subsidiary of Merck, a science and technology company, announced that it will share its partnership strategies and experiences and meet researchers and companies for identifying collaboration opportunities through KPAC (Korea Pharma Associations Conference) 2017 on April 11-12 and Bio Korea 2017 on April 12-14.

Merck Global R&D External Innovation scouts and evaluates external opportunities, including technologies, pre-clinical and early clinical assets in our key therapeutic areas across all geographies. Together with business development, franchise, MS Venture, internal discovery and other R&D function expert teams, Merck considers all possible opportunities that have the potential to create value using innovative deal structures and creative alliances within Merck’s commercial and R&D directions.

Michael Chen, Head of External Innovation based in Beijing R&D Hub of Merck Global R&D will share an overview on Merck healthcare R&D in general, as well as partnering strategies including open innovation strategy and several case examples of successful collaboration opportunities especially in cutting edge technology area and Merck innovation culture at KPAC 2017 and Bio Korea 2017. He will also participate business forum for 1:1 partnering to meet researchers and companies and explore collaboration opportunities in Korea. This visit is the following after his presentation at 5th BioExcellence Conference on the theme “Renaissance of Immunotherapy” organized by Osong Medical Innovation Foundation KBio Health New Drug Development Center on October 10, 2016.

Uloff Muenster, General Manager of Biopharma business, Merck Korea said “Collaboration is one of culture at Merck. The Collaboration and partnership with external innovators are an integral part of delivering our commitment to transform the lives of patients. We are looking forward to connecting Michael Chen and Merck Global R&D experts with researchers and biotech companies in Korea for making the differences by innovation for patients together through globalization.” he added.
Biopharma Business of Merck Korea has been participating in mentoring program at Bio Korea job fair since 2016 to counsel University graduates for career development.

Comments

Hanwha onsure

samsung fire

new energy